The Technical Analyst
Immunocore Holdings plc [IMCR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Immunocore Holdings plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.79% $58.46
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 906.96 mill |
| EPS: | -1.420 |
| P/E: | -41.17 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 49.73 mill |
| Avg Daily Volume: | 0.508 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -41.17 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -7.00x |
| Company: PE -41.17 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.325 (-100.56%) $-58.78 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 55.97 - 60.81 ( +/- 4.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | St Leger Tina Amber | Sell | 4 375 | Employee Share Option (Right to Buy) |
| 2024-04-01 | St Leger Tina Amber | Buy | 4 375 | Ordinary Shares |
| 2024-04-01 | St Leger Tina Amber | Sell | 4 375 | Ordinary Shares |
| 2024-02-28 | Berman David M | Sell | 36 509 | Employee Share Option (Right to Buy) |
| 2024-02-28 | Berman David M | Buy | 36 509 | Ordinary Shares |
| INSIDER POWER |
|---|
| -75.95 |
| Last 63 transactions |
| Buy: 607 651 | Sell: 4 752 433 |
Forecast:
16:00 - $58.46
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $58.46
Forecast 2: 16:00 - $58.46
Forecast 3: 16:00 - $58.46
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $58.46 (0.79% ) |
| Volume | 0.403 mill |
| Avg. Vol. | 0.508 mill |
| % of Avg. Vol | 79.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMCR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $74.69 | N/A | Active |
|---|
IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Latest Press Releases
2024-04-24 10:00:00 - Press Release
Immunocore Announces Upcoming Presentation And Posters At Asco 2024
Immunocore announces upcoming presentation and posters at asco 2024 phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (imc-f106c targeting prame) to be presented during oral abstract session (oxfordshire, england & conshohocken, penn. & rockville, md.
2024-04-04 16:00:00 - Press Release
Immunocore To Present At Upcoming Investor Conferences
Immunocore to present at upcoming investor conferences (oxfordshire, england & conshohocken, penn. & rockville, md.
2024-03-05 16:30:00 - Press Release
Immunocore Presented Two Posters At Croi 2024
Immunocore presented two posters at croi 2024 preclinical data highlights importance of tcr biology in development of new hiv treatments (oxfordshire, england & conshohocken, penn. & rockville, md.
2024-03-01 07:00:00 - Press Release
Immunocore To Present At Upcoming Investor Conferences
Immunocore to present at upcoming investor conferences (oxfordshire, england & conshohocken, penn. & rockville, md.
2024-02-28 07:34:00 - Press Release
Immunocore Reports Fourth Quarter And Full Year 2023 Financial Results And Provides A Business Update
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update kimmtrak (tebentafusp) net revenues of $67.6 million in q4 2023 and $238.7 million in 2023; increasing commercial access to kimmtrak globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma clinical trial collaboration and supply agreement with bristol myers squibb to evaluate imc-f106c (prame hla-a02) with nivolumab in registrational phase 3 first-line advanced cutaneous melanoma trial; prism-mel301 trial to start in 1q 2024 multiple clinical readouts expected to start in 2q 2024 for imc-f106c from phase 1/2 clinical trial monotherapy and combination arms; cta/ind submission for imc-p115c (prame hla-a02 hle) and imc-t119c (prame hla-a24) programs on track for 2024 imc-r117c, a first-in-class immtac targeting piwil1, to begin phase 1 trial in colorectal and other gastrointestinal cancers in 2h 2024 data from imc-m113v phase 1 clinical trial in people living with hiv expected in 2h 2024 advancing novel tcr bispecific clinical candidates for autoimmune diseases cash and cash equivalents of $442...
Latest News
2024-04-04 16:00:00 - GlobeNewsWire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
2024-03-01 07:00:00 - GlobeNewsWire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
2024-02-21 07:00:00 - GlobeNewsWire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
2024-02-13 10:00:30 - Zacks Investment Research
5 Biotech Stocks to Consider for Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
2024-02-01 06:20:14 - Zacks Investment Research
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2024-01-10 07:31:25 - Zacks Investment Research
New Strong Buy Stocks for January 10th
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.
2024-01-03 07:00:00 - GlobeNewsWire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 13:32:16 - Zacks Investment Research
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should Know
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-27 11:17:51 - Zacks Investment Research
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 75.6% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-11-10 11:16:34 - Zacks Investment Research
Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.